Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23665950,objective response rate,The objective response rate was 37.5 %; six additional patients experienced no disease progression for ≥24 weeks.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),%,37.5,2167,DB01268,Sunitinib
,23665950,progression-free survival,Median progression-free survival was 12.5 months.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),month,12.5,2168,DB01268,Sunitinib
,23665950,MTD,The MTD of sunitinib was 25 mg/day on Schedule 2/2 combined with cisplatin/S-1 in patients with advanced/metastatic gastric cancer.,Phase I study of sunitinib plus S-1 and cisplatin in Japanese patients with advanced or metastatic gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23665950/),[mg] / [d],25,2169,DB01268,Sunitinib
,19826424,PFS,"Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7).",Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19826424/),weeks,11.9,10292,DB01268,Sunitinib
,19826424,OS,"Median PFS was 11.9 weeks (95% CI 8.6, 14.1) and median OS was 37.1 weeks (95% CI 31.1, 69.7).",Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19826424/),weeks,37.1,10293,DB01268,Sunitinib
,32358810,time on treatment,"The median time on treatment in patients with RCC who achieved adequate sunitinib exposure (n = 39) was 32 weeks, compared to 15 weeks in patients who did not achieve adequate sunitinib exposure (n = 12) (P = 0.244).",The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32358810/),weeks,32,10439,DB01268,Sunitinib
,32358810,time on treatment,"The median time on treatment in patients with RCC who achieved adequate sunitinib exposure (n = 39) was 32 weeks, compared to 15 weeks in patients who did not achieve adequate sunitinib exposure (n = 12) (P = 0.244).",The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32358810/),weeks,15,10440,DB01268,Sunitinib
,32358810,sum plasma trough concentration (Ctrough ),"In 29 patients (41%) with toxicity leading to dose reduction, sunitinib sum plasma trough concentration (Ctrough ) until dose reduction was significantly higher compared to patients without toxicity leading to dose reduction (median 60 ng/mL vs 44 ng/mL; P < 0.001) and reduced to comparable levels after dose reduction (44 ng/mL; P = 0.488).",The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32358810/),[ng] / [ml],60,10441,DB01268,Sunitinib
,32358810,sum plasma trough concentration (Ctrough ),"In 29 patients (41%) with toxicity leading to dose reduction, sunitinib sum plasma trough concentration (Ctrough ) until dose reduction was significantly higher compared to patients without toxicity leading to dose reduction (median 60 ng/mL vs 44 ng/mL; P < 0.001) and reduced to comparable levels after dose reduction (44 ng/mL; P = 0.488).",The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32358810/),[ng] / [ml],44,10442,DB01268,Sunitinib
,21989766,MTD,"In patients with advanced solid malignancies, the MTD of sunitinib plus 500 mg/m(2) pemetrexed was 37.5 mg/day (CDD schedule) or 50 mg/day (Schedule 2/1).","A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21989766/),mg,37.,12691,DB01268,Sunitinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB01268,Sunitinib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB01268,Sunitinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB01268,Sunitinib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB01268,Sunitinib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB01268,Sunitinib
,30478190,time on treatment,The median time on treatment was 58 days.,"Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30478190/),d,58,12923,DB01268,Sunitinib
,30478190,t 1/2,"X-82 blood pharmacokinetics appeared dose-independent with a t 1/2 of 5.13 hours and 6.48 hours for capsule and tablet formulations, respectively.","Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30478190/),h,5.13,12924,DB01268,Sunitinib
,30478190,t 1/2,"X-82 blood pharmacokinetics appeared dose-independent with a t 1/2 of 5.13 hours and 6.48 hours for capsule and tablet formulations, respectively.","Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30478190/),h,6.48,12925,DB01268,Sunitinib
,31536852,PFS,"At the cut-off date, the median PFS was 4.4 months (95% confidence interval [CI], 2.8-6.0) and 12-week progression-free rate was 73.4% (95% CI, 58.1-88.7).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,4,16206,DB01268,Sunitinib
,31536852,OS,"The median OS was 11.5 months (95% CI, 7.0-not reached).","Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31536852/),month,11.5,16207,DB01268,Sunitinib
,27358594,time of overall survival (OS),"The median time of overall survival (OS) and progression-free survival (PFS) was 27 months (12-61) and 19 months (5-45), respectively.",Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27358594/),month,27,18097,DB01268,Sunitinib
,27358594,progression-free survival (PFS),"The median time of overall survival (OS) and progression-free survival (PFS) was 27 months (12-61) and 19 months (5-45), respectively.",Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27358594/),month,19,18098,DB01268,Sunitinib
,21690570,maximum tolerated dose (MTD),"In patients without these cardiac risk factors, the maximum tolerated dose (MTD) was 15 mg/m(2)/d.",Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690570/),[mg] / [d·m(2)],15,20316,DB01268,Sunitinib
,21690570,MTD,The MTD of sunitinib for patients without risk factors for cardiac toxicity is 15 mg/m(2)/d for 28 days followed by a 14-day break.,Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21690570/),[mg] / [m],15,20317,DB01268,Sunitinib
,22898035,overall response rate,The best response was PR by FDG-PET for five patients (3/12 at 600 mg BIW and 2/9 at 400 TIW) for an overall response rate of 22%.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),%,22,22333,DB01268,Sunitinib
,22898035,response duration,The response duration was 25-138 days.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),d,25-138,22334,DB01268,Sunitinib
,22898035,Cmax,The mean Cmax was 1.5 µmol and the mean AUC was 2.9 µmol h.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),μM,1.5,22335,DB01268,Sunitinib
,22898035,AUC,The mean Cmax was 1.5 µmol and the mean AUC was 2.9 µmol h.,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),h·μM,2.9,22336,DB01268,Sunitinib
>,22898035,Cmax,Cmax>1.5 µmol was associated with a decrease in standardized uptake value (SUVmax).,Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22898035/),μM,1.5,22337,DB01268,Sunitinib
,26813470,plasma AUC0-t,"The plasma AUC0-t for sunitinib in group I was 2051.8 ng × h/mL, whereas in group II it was 3069.3 ng × h/mL.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],2051.8,34323,DB01268,Sunitinib
,26813470,plasma AUC0-t,"The plasma AUC0-t for sunitinib in group I was 2051.8 ng × h/mL, whereas in group II it was 3069.3 ng × h/mL.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],3069.3,34324,DB01268,Sunitinib
,26813470,AUC0-t,"The aqueous humour AUC0-t for sunitinib in thr groups were 43.2 and 76.3 ng × h/mL, respectively.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],43.2,34325,DB01268,Sunitinib
,26813470,AUC0-t,"The aqueous humour AUC0-t for sunitinib in thr groups were 43.2 and 76.3 ng × h/mL, respectively.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],76.3,34326,DB01268,Sunitinib
,26813470,cerebrospinal AUC0-t,"The cerebrospinal AUC0-t for sunitinib in groups I and II were 55.5 and 66.3 ng × h/mL, respectively.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],55.5,34327,DB01268,Sunitinib
,26813470,cerebrospinal AUC0-t,"The cerebrospinal AUC0-t for sunitinib in groups I and II were 55.5 and 66.3 ng × h/mL, respectively.",The influence of the time-of-day administration of sunitinib on the penetration through the blood-brain and blood-aqueous humour barriers in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26813470/),[h·ng] / [ml],66.3,34328,DB01268,Sunitinib
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,29,35087,DB01268,Sunitinib
,24365125,Objective response rates,Objective response rates were 29% (trebananib plus sorafenib) and 53% (trebananib plus sunitinib).,"A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365125/),%,53,35088,DB01268,Sunitinib
>,25344452,area under the curve (AUC),"A high composite area under the curve (AUC) >1,973 ng/mL∙h at day 21 was associated with a doubled survival (35.2 vs 16.7 months; log-rank p = 0.0051) in renal cancer patients.",Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25344452/),[ng] / [ml∙h],"1,973",35224,DB01268,Sunitinib
,28917151,droplet size,The average droplet size of sunitinib-loaded SNEDDS was 29.5±6.3nm with a stability of more than one month.,A novel self-nanoemulsifying formulation for sunitinib: Evaluation of anticancer efficacy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28917151/),nm,29.5,39865,DB01268,Sunitinib
above,19737946,total drug trough concentrations,"On the 50-mg dose across all schedules, 79% of PK-evaluable patients achieved total drug trough concentrations above the target concentration (50 ng/mL) within 14 days of dosing.","Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19737946/),[ng] / [ml],50,39980,DB01268,Sunitinib
,24676873,maximum plasma concentration,"The maximum plasma concentration of paracetamol glucuronide tended to be higher in group PC 213.27 μg/mL (90 % CI 1.06, 1.25; p = 0.0267).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),[μg] / [ml],213.27,44107,DB01268,Sunitinib
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,15,44108,DB01268,Sunitinib
,24676873,t max,"The mean t max of paracetamol glucuronide was similar in both groups: SUN + PC and group PC (15 and 20 min, respectively).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),min,20,44109,DB01268,Sunitinib
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,10.0,44110,DB01268,Sunitinib
,24676873,t max,"The mean t max of sunitinib was different in groups SUN + PC and SUN (10.0 and 7.0, respectively; p = 0.0134).",The effect of sunitinib on the plasma exposure of intravenous paracetamol and its major metabolite: paracetamol glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24676873/),,7.0,44111,DB01268,Sunitinib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.18,46174,DB01268,Sunitinib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.23,46175,DB01268,Sunitinib
,30503942,IC50,"The ureido analogue 6u emerged as the most potent multikinase inhibitor in the ureido series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.18, 0.23 and 0.10 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.10,46176,DB01268,Sunitinib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.28,46177,DB01268,Sunitinib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.46,46178,DB01268,Sunitinib
,30503942,IC50,"Whereas, the amido congener 10j emerged as the most potent multikinase inhibitor in the amide series with VEGFR-2, FGFR-1 and PDGFR-b IC50 of 0.28, 0.46 and 0.09 μM, respectively.","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.09,46179,DB01268,Sunitinib
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,2.67,46180,DB01268,Sunitinib
,30503942,IC50,"While, indolinone 6u was the most potent derivative towards HepG2 cells (IC50 = 2.67 ± 0.14 μM), 6r stood out as the most potent indolinone against A498 cells (IC50 = 0.78 ± 0.02 μM).","Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30503942/),μM,0.78,46181,DB01268,Sunitinib
,18347007,overall response rate,"Seven patients achieved a partial response (median duration, 19 weeks), giving an overall response rate of 11%.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),%,11,49557,DB01268,Sunitinib
,18347007,time to progression,"Median time to progression and overall survival were 10 and 38 weeks, respectively.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),weeks,10,49558,DB01268,Sunitinib
,18347007,overall survival,"Median time to progression and overall survival were 10 and 38 weeks, respectively.","Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18347007/),weeks,38,49559,DB01268,Sunitinib
,20512335,AUC(0-24 h)),The effect of GJ on CYP3A4 activity was confirmed by an increase of ~50% of mean midazolam exposure (AUC(0-24 h)) from 122.1 to 182.0 ng h/mL (P = 0.034).,Marginal increase of sunitinib exposure by grapefruit juice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20512335/),[h·ng] / [ml],122.1,52227,DB01268,Sunitinib
,20512335,AUC(0-24 h)),The effect of GJ on CYP3A4 activity was confirmed by an increase of ~50% of mean midazolam exposure (AUC(0-24 h)) from 122.1 to 182.0 ng h/mL (P = 0.034).,Marginal increase of sunitinib exposure by grapefruit juice. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20512335/),[h·ng] / [ml],182.0,52228,DB01268,Sunitinib
,24533632,flow rate,"Linifanib was separated on Acquity UPLC BEH™ C18 column (50 × 2.1 mm, i.d. 1.7 μm) using acetonitrile-10 mM ammonium acetate (60:40, v/v) as an isocratic mobile phase at a flow rate of 0.3 mL/min with sunitinib as internal standard (IS).","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),[ml] / [min],0.3,55314,DB01268,Sunitinib
,24533632,m/z,"The monitored transitions were set at m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively.","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),,376.05,55315,DB01268,Sunitinib
>,24533632,m/z,"The monitored transitions were set at m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively.","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),,250.97,55316,DB01268,Sunitinib
>,24533632,m/z,"The monitored transitions were set at m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively.","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),,399.12,55317,DB01268,Sunitinib
>,24533632,m/z,"The monitored transitions were set at m/z 376.05 > 250.97 for linifanib and m/z 399.12 >283.02 for IS, respectively.","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),,283.02,55318,DB01268,Sunitinib
,24533632,total run time,"Both linifanib and IS were eluted at 0.68 and 0.44 min, respectively with a total run time of 2.0 min only.","Simple, sensitive and rapid determination of linifanib (ABT-869), a novel tyrosine kinase inhibitor in rat plasma by UHPLC-MS/MS. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24533632/),min,2.0,55319,DB01268,Sunitinib
,25647628,C trough-1,(C trough-1 p.m. 66.0 ng/mL; C trough-6 p.m. 58.9 ng/mL; C trough-8 a.m. 50.7 ng/mL; p = 0.006).,Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647628/),[ng] / [ml],66.0,56742,DB01268,Sunitinib
,25647628,C trough-6,(C trough-1 p.m. 66.0 ng/mL; C trough-6 p.m. 58.9 ng/mL; C trough-8 a.m. 50.7 ng/mL; p = 0.006).,Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647628/),[ng] / [ml],58.9,56743,DB01268,Sunitinib
,25647628,C trough-8 a,(C trough-1 p.m. 66.0 ng/mL; C trough-6 p.m. 58.9 ng/mL; C trough-8 a.m. 50.7 ng/mL; p = 0.006).,Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25647628/),[ng] / [ml],50.7,56744,DB01268,Sunitinib
,19797000,run time,"Following single organic extraction with tert-butyl methyl ether, HPLC analysis was performed on an ODS column and UV detection was monitored at 369 nm (run time 15 min).","A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19797000/),min,15,59997,DB01268,Sunitinib
,26174223,time receiving drug,Mean time receiving drug was 99 days.,A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26174223/),d,99,65360,DB01268,Sunitinib
,21140147,AUC,"Successive cohorts of patients with advanced solid tumors received oral sunitinib (25, 37.5, or 50 mg) for 2 consecutive weeks of a 3-week cycle (Schedule 2/1) or as a continuous daily dose for 3-week cycles (CDD schedule) in combination with paclitaxel (175-200 mg/m(2)) plus carboplatin (AUC 6 mg min/ml) on day one of each of 4 cycles.",Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21140147/),[mg·min] / [ml],6,65955,DB01268,Sunitinib
,21140147,AUC,The MTD for Schedule 2/1 was sunitinib 25 mg plus paclitaxel 175 mg/m(2) and carboplatin AUC 6 mg min/ml.,Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21140147/),[mg·min] / [ml],6,65956,DB01268,Sunitinib
,25393890,clearance,"The clearance of sunitinib and SU12662 was estimated at 35.7 (relative standard error (RSE) 5.7%) l h(-1) and 17.1 (RSE 7.4%) l h(-1), respectively for 70 kg patients.",Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393890/),[l] / [h],35.7,66598,DB01268,Sunitinib
,25393890,clearance,"The clearance of sunitinib and SU12662 was estimated at 35.7 (relative standard error (RSE) 5.7%) l h(-1) and 17.1 (RSE 7.4%) l h(-1), respectively for 70 kg patients.",Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25393890/),[l] / [h],17.1,66599,DB01268,Sunitinib
,20461441,OS,"Median PFS was 2.3 months (95% confidence interval [CI], 1.6-2.6 months) and median OS was 6.8 months (95% CI, 4.4-9.6 months).",Phase II study of sunitinib as second-line treatment for advanced gastric cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20461441/),month,6,70061,DB01268,Sunitinib
,21447616,objective response rate,"At the MTD, non-haematologic grade 3/4 adverse events with a frequency of >10% were diarrhoea, vomiting and lethargy, and the objective response rate was 57.9% (95% confidence interval 33.5-79.7).",A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),%,57.,73220,DB01268,Sunitinib
,21447616,MTD,The MTD of sunitinib combined with FOLFIRI in chemotherapy-naive mCRC was 37.5 mg/day on Schedule 4/2.,A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447616/),[mg] / [d],37.5,73221,DB01268,Sunitinib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],283,78451,DB01268,Sunitinib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],494,78452,DB01268,Sunitinib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],738,78453,DB01268,Sunitinib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],1071,78454,DB01268,Sunitinib
,24417304,Progression-free survival (PFS),Progression-free survival (PFS) in this first-line group was longer for patients that started with full-dose sunitinib (21·1 months; n = 12) than for patients started on reduced dose (3·5 months; n = 10).,Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417304/),month,21·1,82938,DB01268,Sunitinib
,24417304,Progression-free survival (PFS),Progression-free survival (PFS) in this first-line group was longer for patients that started with full-dose sunitinib (21·1 months; n = 12) than for patients started on reduced dose (3·5 months; n = 10).,Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24417304/),month,3·5,82939,DB01268,Sunitinib
,21898376,Objective response rate (ORR),Objective response rate (ORR) was 35.3%; median response duration was 10.4 months; 36% of patients had stable disease ≥12 weeks.,Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898376/),%,35.3,86469,DB01268,Sunitinib
,21898376,response duration,Objective response rate (ORR) was 35.3%; median response duration was 10.4 months; 36% of patients had stable disease ≥12 weeks.,Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21898376/),month,10,86470,DB01268,Sunitinib
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],21.4,87213,DB01268,Sunitinib
,24234588,trough concentration,"In 52 patients, the mean trough concentration of sunitinib plus metabolite increased from 21.4 ng/mL at day 1 of a cycle to 88.1 ng/mL in the fourth week of treatment.",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[ng] / [ml],88.1,87214,DB01268,Sunitinib
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],34.4,87215,DB01268,Sunitinib
,24234588,clearance,"Moreover, patients suffering from grade 3 toxicities had significant lower clearance of sunitinib than patients without grade 3 toxicities (34.4 vs. 41.4 L/h; P = 0.025).",Predictive value of CYP3A and ABCB1 phenotyping probes for the pharmacokinetics of sunitinib: the ClearSun study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24234588/),[l] / [h],41.4,87216,DB01268,Sunitinib
,22460270,TTP,The TTP was not significantly prolonged in the DS arm when compared with the D only arm (DS vs D only arm: 3.9 months (95% confidence interval (CI) 2.9-4.9) vs 2.6 months (95% CI 1.8-3.5) (P=0.206).,Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),month,3.9,91287,DB01268,Sunitinib
,22460270,TTP,The TTP was not significantly prolonged in the DS arm when compared with the D only arm (DS vs D only arm: 3.9 months (95% confidence interval (CI) 2.9-4.9) vs 2.6 months (95% CI 1.8-3.5) (P=0.206).,Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),month,2.6,91288,DB01268,Sunitinib
,22460270,objective response rate,"However, the objective response rate was significantly higher in the DS arm (41.1% vs 14.3%, P=0.002).",Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),%,41.1,91289,DB01268,Sunitinib
,22460270,objective response rate,"However, the objective response rate was significantly higher in the DS arm (41.1% vs 14.3%, P=0.002).",Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22460270/),%,14.3,91290,DB01268,Sunitinib
,29055166,"AUCƬ,ss","Using the ROC curve, the threshold value of composite AUCƬ,ss predicting grade ≥3 toxicity was 2150 ng/mL/h (CI 95%, 0.6-0.79%; P < 0.0001).",Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055166/),[ng] / [h·ml],2150,94206,DB01268,Sunitinib
,29055166,"AUCƬ,ss","At disease progression in patients with mRCC, AUCƬ,ss tended to be lower than the one assayed during the first cycle (1678 vs. 2004 ng/mL/h, respectively, P = 0.072).",Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055166/),[ng] / [h·ml],1678,94207,DB01268,Sunitinib
,29055166,"AUCƬ,ss","At disease progression in patients with mRCC, AUCƬ,ss tended to be lower than the one assayed during the first cycle (1678 vs. 2004 ng/mL/h, respectively, P = 0.072).",Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29055166/),[ng] / [h·ml],2004,94208,DB01268,Sunitinib
,24409000,flow rate,"The mobile phase consisted of 20 mM ammonium formate (with 0.1 % formic acid): acetonitrile (70:30, v/v) pumped isocratically at a flow rate of 0.25 mL min-1 with a total run-time of 13 min.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),[ml] / [min],0.25,98557,DB01268,Sunitinib
,24409000,total run-time,"The mobile phase consisted of 20 mM ammonium formate (with 0.1 % formic acid): acetonitrile (70:30, v/v) pumped isocratically at a flow rate of 0.25 mL min-1 with a total run-time of 13 min.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,13,98558,DB01268,Sunitinib
,24409000,retention times,"The retention times of sunitinib and dasatinib were 7.8 and 5.5 min, respectively.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,7.8,98559,DB01268,Sunitinib
,24409000,retention times,"The retention times of sunitinib and dasatinib were 7.8 and 5.5 min, respectively.",Sunitinib LC-MS/MS Assay in Mouse Plasma and Brain Tissue: Application in CNS Distribution Studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24409000/),min,5.5,98560,DB01268,Sunitinib
,20142724,objective response rate,"Thirteen patients treated at the MTD achieved a partial response (objective response rate: 37%; 95% confidence interval, 22-55) and 12 (34%) had stable disease.",Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20142724/),%,37,98967,DB01268,Sunitinib
,20142724,progression-free survival,"Median progression-free survival was 11 months (95% confidence interval, 6-17).",Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20142724/),month,11,98968,DB01268,Sunitinib
,23978989,plasma Cmax,"After 5 mg/kg i.v., OTX008 achieved plasma Cmax of 14.39 μg/mL, distributed rapidly, and was eliminated with a half-life of 31.4 h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),[μg] / [ml],14.39,99855,DB01268,Sunitinib
,23978989,half-life,"After 5 mg/kg i.v., OTX008 achieved plasma Cmax of 14.39 μg/mL, distributed rapidly, and was eliminated with a half-life of 31.4 h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),h,31.4,99856,DB01268,Sunitinib
,23978989,Cmax,"Tumor OTX008 Cmax (1.65 μg/g, 1.76 μM), achieved at 0.5 h, remained high at 24 h (0.516 μg/g, 0.55 μM) with AUC of 15.76 μg/g*h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),[μg] / [g],1.65,99857,DB01268,Sunitinib
,23978989,Cmax,"Tumor OTX008 Cmax (1.65 μg/g, 1.76 μM), achieved at 0.5 h, remained high at 24 h (0.516 μg/g, 0.55 μM) with AUC of 15.76 μg/g*h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),μM,1.76,99858,DB01268,Sunitinib
,23978989,Cmax,"Tumor OTX008 Cmax (1.65 μg/g, 1.76 μM), achieved at 0.5 h, remained high at 24 h (0.516 μg/g, 0.55 μM) with AUC of 15.76 μg/g*h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),[μg] / [g],0.516,99859,DB01268,Sunitinib
,23978989,Cmax,"Tumor OTX008 Cmax (1.65 μg/g, 1.76 μM), achieved at 0.5 h, remained high at 24 h (0.516 μg/g, 0.55 μM) with AUC of 15.76 μg/g*h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),μM,0.55,99860,DB01268,Sunitinib
,23978989,AUC,"Tumor OTX008 Cmax (1.65 μg/g, 1.76 μM), achieved at 0.5 h, remained high at 24 h (0.516 μg/g, 0.55 μM) with AUC of 15.76 μg/g*h.",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),[μg] / [g·h],15.76,99861,DB01268,Sunitinib
,23978989,IC50,"Tumor cell proliferation was also inhibited, with differences in sensitivity among cell lines (IC50 from 1 to 190 μM).",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),μM,1,99862,DB01268,Sunitinib
,23978989,IC50,"Tumor cell proliferation was also inhibited, with differences in sensitivity among cell lines (IC50 from 1 to 190 μM).",Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23978989/),μM,190,99863,DB01268,Sunitinib
,28038328,IC50,"Compound 10a and 10d exhibited better efficacy (MV4-11, IC50: 14.7 nM for 10a and 24.8 nM for 10d) than positive control sunitinib (MV4-11, IC50: 38.5 nM).","Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28038328/),nM,14.7,100509,DB01268,Sunitinib
,28038328,IC50,"Compound 10a and 10d exhibited better efficacy (MV4-11, IC50: 14.7 nM for 10a and 24.8 nM for 10d) than positive control sunitinib (MV4-11, IC50: 38.5 nM).","Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28038328/),nM,24.8,100510,DB01268,Sunitinib
,28038328,IC50,"Compound 10a and 10d exhibited better efficacy (MV4-11, IC50: 14.7 nM for 10a and 24.8 nM for 10d) than positive control sunitinib (MV4-11, IC50: 38.5 nM).","Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28038328/),nM,38.5,100511,DB01268,Sunitinib
,28038328,IC50,"The kinase and cellular inhibition assay exhibited that 10d (FLT3, IC50: 5.3 nM) was a potent and selective FLT3 inhibitor.","Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28038328/),nM,5.3,100512,DB01268,Sunitinib
<,24736581,total trough level (TTL),"If the total trough level (TTL) was <50 ng ml(-1) and the patient did not show any grade ⩾3 toxicity, the daily sunitinib dose was increased by 12.5 mg.",Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24736581/),[ng] / [ml],50,102191,DB01268,Sunitinib
,23108983,flow rate,"After simple one-step protein precipitation with methanol-acetonitrile (1:1, v/v), all three analytes were separated on an Agilent Zorbax SB-C(18) column using a gradient mobile phase consisting of water (0.1% formic acid)-acetonitrile (0.1% formic acid) at a flow rate of 0.50 mL/min.",Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108983/),[ml] / [min],0.50,112014,DB01268,Sunitinib
,23108983,recoveries,The intra-day and inter-day precisions were all less than 15% and the accuracies were within the range of ±15%; recoveries were between 85.0 and 115%.,Simultaneous determination of sunitinib and its two metabolites in plasma of Chinese patients with metastatic renal cell carcinoma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108983/),%,85.0 and 115,112015,DB01268,Sunitinib
,21439816,clinical benefit rate,"Two patients (8%) achieved a partial response (PR) and 7 patients (29%) had stabilisation of their disease (SD) >6months, for a clinical benefit rate of 37.5%.",Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21439816/),,37,112050,DB01268,Sunitinib
≥,28185218,trough level,"Furthermore, a strong relationship between pazopanib trough level ≥20 mg/L and both tumor shrinkage and progression-free survival has been established.",Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185218/),[mg] / [l],20,115836,DB01268,Sunitinib
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.8,138323,DB01268,Sunitinib
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,14.6,138324,DB01268,Sunitinib
,25656737,tissue-to-plasma AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,2.25,138325,DB01268,Sunitinib
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,31.4,138326,DB01268,Sunitinib
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,17.1,138327,DB01268,Sunitinib
,25656737,AUC0→∞ ratio,"Sunitinib presented high tissue-to-plasma AUC0→∞ ratio in liver (17.8 ± 1.2), kidney (14.6 ± 1.52) and brain (2.25 ± 0.18) which was modified after coadministration: AUC0→∞ ratio increased in liver (31.4 ± 4.7; p < 0.001), kidney (17.1 ± 2.2; p > 0.05) and decreased in brain (1.70 ± 0.23, p > 0.05).",Sunitinib tissue distribution changes after coadministration with ketoconazole in mice. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25656737/),,1.70,138328,DB01268,Sunitinib
,25389456,peak blood level,"The mean peak blood level of sunitinib in patients with fractioned doses was significantly lower than that in those with once-daily dose (83.4 vs 50.1 ng/ml, P = .01).",Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389456/),[ng] / [ml],83.4,139098,DB01268,Sunitinib
,25389456,peak blood level,"The mean peak blood level of sunitinib in patients with fractioned doses was significantly lower than that in those with once-daily dose (83.4 vs 50.1 ng/ml, P = .01).",Fractioned dose regimen of sunitinib for patients with gastrointestinal stromal tumor: a pharmacokinetic and treatment efficacy study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25389456/),[ng] / [ml],50.1,139099,DB01268,Sunitinib
,31471313,progression-free survival,"Stable disease was the best response in 4 patients, and median progression-free survival was 1.9 months.",Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471313/),month,1.9,151029,DB01268,Sunitinib
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.98,164651,DB01268,Sunitinib
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.76,164652,DB01268,Sunitinib
,18971416,brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio,The brain tumor-to-plasma steady-state TMZ concentration (ss C(t)/C(p)) ratio was significantly increased in the 20 mg/kg sunitinib group (0.98 +/- 0.17) compared with the control (0.76 +/- 0.17) and 60 mg/kg sunitinib (0.68 +/- 0.09) groups.,Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18971416/),,0.68,164653,DB01268,Sunitinib
,27485537,CL/F,"Sunitinib population means for CL/F and V d /F central were 13.8 L/h and 1720 L, respectively.",BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27485537/),[l] / [h],13.8,164823,DB01268,Sunitinib
,27485537,V d /F central,"Sunitinib population means for CL/F and V d /F central were 13.8 L/h and 1720 L, respectively.",BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27485537/),l,1720,164824,DB01268,Sunitinib
,27485537,CL/F,"SU12662 population means for CL/F and V d /F were 42.1 L/h and 1410 L, respectively.",BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27485537/),[l] / [h],42.1,164825,DB01268,Sunitinib
,27485537,V d /F,"SU12662 population means for CL/F and V d /F were 42.1 L/h and 1410 L, respectively.",BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27485537/),l,1410,164826,DB01268,Sunitinib
,21174612,MTD,The MTD was 3 microg/kg rIL-21 combined with sunitinib 50 mg OD at the '4 weeks on/2 weeks off' schedule.,A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21174612/),[μg] / [kg],3,170911,DB01268,Sunitinib
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,938",174365,DB01268,Sunitinib
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"2,002",174366,DB01268,Sunitinib
,20049443,AUC(0-infinity),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,999",174367,DB01268,Sunitinib
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,913",174368,DB01268,Sunitinib
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,956",174369,DB01268,Sunitinib
,20049443,AUC(0-last),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[h·ng] / [ml],"1,958",174370,DB01268,Sunitinib
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],26.0,174371,DB01268,Sunitinib
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],27.3,174372,DB01268,Sunitinib
,20049443,C (max),"In subjects with normal hepatic function, mild, or moderate hepatic impairment, respectively, TD AUC(0-infinity) was 1,938, 2,002, and 1,999 ng h/ml, TD AUC(0-last) was 1,913, 1,956, and 1,958 ng h/ml, and TD C (max) was 26.0, 27.3, and 26.7 ng/ml.",Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20049443/),[ng] / [ml],26.7,174373,DB01268,Sunitinib
,30834940,progression-free survival (PFS),"In an interim analysis of a Phase II trial in Japanese patients with pancreatic neuroendocrine tumors (panNETs), sunitinib demonstrated antitumor activity with an objective response rate (ORR) of 50% (95% confidence interval [CI], 21-79) and a median progression-free survival (PFS) of 16.8 months (95% CI, 9.3-26.2).","Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30834940/),month,16,175939,DB01268,Sunitinib
,30834940,number,The median (range) number of days on drug was 323.5 (22-727).,"Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30834940/),,323.5,175940,DB01268,Sunitinib
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,61,180535,DB01268,Sunitinib
,23108697,relative dose intensity,"Cumulative myelosuppression was problematic: the median relative dose intensity (% actual/intended) across all cycles was 61 % for sunitinib, 78 % for pemetrexed, and 74 % for cisplatin.","Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23108697/),,78,180536,DB01268,Sunitinib
,25701374,total sunitinib concentration,"The median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL).",Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25701374/),[ng] / [ml],91.8,181171,DB01268,Sunitinib
,25701374,TTF,"Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02).",Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25701374/),d,590,181172,DB01268,Sunitinib
,25701374,TTF,"Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02).",Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25701374/),d,71,181173,DB01268,Sunitinib
,25701374,PFS,"Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02).",Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25701374/),d,74,181174,DB01268,Sunitinib
,25701374,PFS,"Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02).",Assessment of Sunitinib-Induced Toxicities and Clinical Outcomes Based on Therapeutic Drug Monitoring of Sunitinib for Patients With Renal Cell Carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25701374/),d,238,181175,DB01268,Sunitinib
,25044855,recoveries,Liquid-liquid extraction with a mixture of n-hexane/isopropanol (90:10 v/v) allowed recoveries at the level of 70%.,Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044855/),%,70,186134,DB01268,Sunitinib
,25044855,A/B ratio,"Measurements were performed using a Zorbax SB-C18 column (3.0 mm × 150 mm, 3.5 μm) and isocratic elution with (A) 0.1% aqueous formic acid and (B) acetonitrile/methanol (80:20 v/v) in an A/B ratio of 55:45 at 35°C.",Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044855/),,55:45,186135,DB01268,Sunitinib
,25044855,total run time,"Under these conditions, sunitinib is eluted at 3.8 min in 6 min of the total run time.",Determination of sunitinib in human plasma using liquid chromatography coupled with mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25044855/),min,6,186136,DB01268,Sunitinib
,20957481,progression-free survival (PFS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,23.6,186383,DB01268,Sunitinib
,20957481,overall survival (OS),"Median progression-free survival (PFS) and overall survival (OS) were 23.6 weeks (95% confidence interval [CI] 0.0-50.6 weeks) and 74.0 weeks (95% CI 27.4-120.6 weeks), respectively.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),weeks,74.0,186384,DB01268,Sunitinib
,20957481,C (max),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[μg] / [l],"1,754",186385,DB01268,Sunitinib
,20957481,T(1/2),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),h,13.4,186386,DB01268,Sunitinib
,20957481,AUC (0-12 h),"Pharmacokinetic parameters of nilotinib were as follows: C (max) of 1,754 ± 970 μg/L, T(1/2) of 13.4 ± 8.94 h and AUC (0-12 h) of 14,190 ± 6,853 h μg/L.",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"14,190",186387,DB01268,Sunitinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"8,526",186388,DB01268,Sunitinib
,20957481,AUC (0-12 h),"The AUC (0-12 h) of nilotinib was significantly lower in the 4 patients with prior major (total or subtotal) gastrectomy than in the other 13 patients (8,526 ± 7,869 h μg/L vs. 15,930 ± 5,759 h μg/L, P = 0.014).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"15,930",186389,DB01268,Sunitinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"1,914",186390,DB01268,Sunitinib
,20957481,AUC (0-12 h),"Of the 4 gastrectomized patients, two (50%) showed markedly decreased nilotinib exposure (AUC (0-12 h) of 1,914 and 3,194 h μg/L) and rapid disease progression (PFS of 4.6 and 7.1 weeks).",Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20957481/),[h·μg] / [l],"3,194",186391,DB01268,Sunitinib
higher,29861870,C0 level,"Patients with DSU C0 level higher than 15.0 ng/mL showed a tendency toward increased PFS (61 weeks vs 12 weeks, p = 0.004) and OS (36 months vs 8 months, p = 0.040).",Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29861870/),[ng] / [ml],15.0,187335,DB01268,Sunitinib
>,29861870,C0,The higher level of C0 of SU may predict developing AEs and DSU C0 >15.0 ng/mL may lead to better prognosis of patients treated with sunitinib.,Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29861870/),[ng] / [ml],15.0,187336,DB01268,Sunitinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],931,188378,DB01268,Sunitinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],1177,188379,DB01268,Sunitinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],354,188380,DB01268,Sunitinib
,25102852,"AUC24,ss","The geometric mean of sunitinib and SU12662 AUC24,ss was decreased by 21% and 28% in patients with both gastrectomy and small bowel resection (n = 8) compared to controls (n = 63) for sunitinib (931 ng hr/mL (95%-CI; 676-1283) versus 1177 ng hr/mL (95%-CI; 1097-1263); p < 0.05) and SU12662 (354 ng hr/mL (95%-CI; 174-720) versus 492 ng hr/mL (95%-CI; 435-555); p < 0.05).",Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25102852/),[h·ng] / [ml],492,188381,DB01268,Sunitinib
,24468044,total release,"A total release of 80% in saline was measured, with similar fast-release profiles for both sphere sizes.",Drug-eluting beads loaded with antiangiogenic agents for chemoembolization: in vitro sunitinib loading and release and in vivo pharmacokinetics in an animal model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24468044/),%,80,190105,DB01268,Sunitinib
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],7.6,193012,DB01268,Sunitinib
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],139.0,193013,DB01268,Sunitinib
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],12,193014,DB01268,Sunitinib
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],409.6,193015,DB01268,Sunitinib
,21220434,AUC(0)(-),"The four mitotane-treated patients showed highly induced CYP3A4 activity, even after interrupting mitotane therapy months before study entry, reflected by decreased midazolam exposure compared with the other seven patients (mean AUC(0)(-)(12 h) (95% CI): 7.6 (5.5-9.7) vs 139.0 (95.1-182.9) μg×h/l respectively P=0.001) and increased 1-hydroxy-midazolam exposure (mean AUC(0)(-)(12 h) (95% CI): 409.6 (290.5-528.7) vs 35.0 (26.4-43.6) μg×h/l, P=0.008).",Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],35.0,193016,DB01268,Sunitinib
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],267,193017,DB01268,Sunitinib
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],268,193018,DB01268,Sunitinib
,21220434,exposure,Sunitinib exposure was decreased in the two patients who were co-treated with mitotane (267 and 268 μg×h/l versus 1344 (1079-1609) (mean (95% CI)) μg×h/l).,Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21220434/),[h·μg] / [l],1344,193019,DB01268,Sunitinib
,25294592,flow rate,"The analytes were separated by an isocratic mobile phase consisting of acetonitrile and buffer solution (water with 0.1% formic acid and 5 m m ammonium acetate; 40: 60, v/v) running at a flow rate of 0.35 mL/min for 2 min.","Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294592/),[ml] / [min],0.35,195418,DB01268,Sunitinib
,25294592,half-life,"The pharmacokinetic study indicated that sunitinib was eliminated quickly in mice with a half-life of 1.2 h; tissue distribution data showed more sunitinib and its metabolite in liver, spleen and lung, which provided reference for further study.","Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse plasma and tissues by UPLC-MS/MS: assay development and application to pharmacokinetic and tissue distribution studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294592/),h,1.2,195419,DB01268,Sunitinib
,19258444,CL/F,"Sunitinib parameters were estimated as CL/F, 51.8 L/h and Vd/F(central), 2,030 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),[l] / [h],51.8,199094,DB01268,Sunitinib
,19258444,Vd/F(central),"Sunitinib parameters were estimated as CL/F, 51.8 L/h and Vd/F(central), 2,030 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),l,"2,030",199095,DB01268,Sunitinib
,19258444,CL/F,"SU12662 parameters were estimated as CL/F, 29.6 L/h and Vd/F(central), 3,080 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),[l] / [h],29.6,199096,DB01268,Sunitinib
,19258444,Vd/F(central),"SU12662 parameters were estimated as CL/F, 29.6 L/h and Vd/F(central), 3,080 liters.",A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19258444/),l,"3,080",199097,DB01268,Sunitinib
,34020239,IC50,"The cytotoxicity screening pointed toward the N-cyclohexyl thiazolidinone derivative 4f that revealed promising renal cytotoxicity against CAKI-1 and UO-31 renal cancer cell lines with IC50 values 4.74 and 3.99 µM, respectively, which were comparable to those of sunitinib along with good safety threshold against normal renal cells.",Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020239/),μM,4.74,206363,DB01268,Sunitinib
,34020239,IC50,"The cytotoxicity screening pointed toward the N-cyclohexyl thiazolidinone derivative 4f that revealed promising renal cytotoxicity against CAKI-1 and UO-31 renal cancer cell lines with IC50 values 4.74 and 3.99 µM, respectively, which were comparable to those of sunitinib along with good safety threshold against normal renal cells.",Insight on a new indolinone derivative as an orally bioavailable lead compound against renal cell carcinoma. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34020239/),μM,3.99,206364,DB01268,Sunitinib
,24874929,TTDR,We observed an increased TTDR in patients carrying the TT-genotype in ABCB1 rs1125803 compared to patients with CC- or CT-genotypes (19 vs.,Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874929/),,19,228164,DB01268,Sunitinib
,24874929,TTDR,7 cycles; p = 0.031 on univariate analysis and p = 0.012 on multivariate analysis) and an increased TTDR in patients carrying the TT/TA-variant in ABCB1 rs2032582 compared to patients with the GG- or GT/GA-variant (19 vs. 7 cycles; p = 0.046 on univariate analysis and p = 0.024 on multivariate analysis).,Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874929/),cycles,19,228165,DB01268,Sunitinib
,24874929,TTDR,7 cycles; p = 0.031 on univariate analysis and p = 0.012 on multivariate analysis) and an increased TTDR in patients carrying the TT/TA-variant in ABCB1 rs2032582 compared to patients with the GG- or GT/GA-variant (19 vs. 7 cycles; p = 0.046 on univariate analysis and p = 0.024 on multivariate analysis).,Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24874929/),cycles,7,228166,DB01268,Sunitinib
,23963796,AUC,Pemetrexed (400-500 mg/m(2) IV) and carboplatin (AUC = 5 mg·min/ml IV) were administered q3w.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237840,DB01268,Sunitinib
,23963796,AUC,The MTD on Schedule 2/1 was sunitinib 37.5 mg/day with pemetrexed 500 mg/m(2) and carboplatin AUC = 5 mg·min/ml; MTD on the CDD schedule was not established.,Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg·min] / [ml],5,237841,DB01268,Sunitinib
,23963796,MTD,"With this combination, in patients with advanced solid malignancies, sunitinib MTD on Schedule 2/1 was 37.5 mg/day.",Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23963796/),[mg] / [d],37.5,237842,DB01268,Sunitinib
,22970046,trough concentration,"On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l.",Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22970046/),[ng] / [ml],46.1,238149,DB01268,Sunitinib
,22970046,area under the curve (AUC),"On day 7, the trough concentration of sunitinib plus SU12662 was 46.1 ng/ml and the area under the curve (AUC) was 1,393.0 ng·h/l.",Treatment of a GIST patient with modified dose of sunitinib by measurement of plasma drug concentrations. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22970046/),[h·ng] / [l],"1,393.0",238150,DB01268,Sunitinib
,22615059,MTD,The MTD of sunitinib was established as 25 mg/day on Schedule 2/1.,"A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22615059/),[mg] / [d],25,241763,DB01268,Sunitinib
,31006038,progression-free survival,Median progression-free survival was 5.8 months (95% CI 2.3-not reached).,Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31006038/),month,5.8,242507,DB01268,Sunitinib
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,6.4,242929,DB01268,Sunitinib
,24091982,progression-free survival,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),month,5.5-8.0,242930,DB01268,Sunitinib
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,46.7,242931,DB01268,Sunitinib
,24091982,objective response rate,"At the MTDs, median progression-free survival was 6.4 months and 5.5-8.0 months for sunitinib/XP and sunitinib/XELOX, respectively; and the objective response rate was 46.7% and 43.5-45.5% for sunitinib/XP and sunitinib/XELOX, respectively.",Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24091982/),%,43.5-45.5,242932,DB01268,Sunitinib
,19655144,maximum concentrations (C(max)),Mean maximum concentrations (C(max)) were reached during the first day of treatment for sunitinib at 38.98 (+ or - 22.66) ng/ml and for SU012662 at 11.12 (+ or - 24.57) ng/ml.,A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655144/),[ng] / [ml],38.98,248758,DB01268,Sunitinib
,19655144,maximum concentrations (C(max)),Mean maximum concentrations (C(max)) were reached during the first day of treatment for sunitinib at 38.98 (+ or - 22.66) ng/ml and for SU012662 at 11.12 (+ or - 24.57) ng/ml.,A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19655144/),[ng] / [ml],11.12,248759,DB01268,Sunitinib
,24778032,systemic clearance,"The corresponding pharmacokinetic parameters of systemic clearance and volume of distribution at steady-state of sunitinib were significantly larger in analbuminemic rats (2.17 l/h/kg and 3.94 l/kg, respectively) than those in SD rats (1.26 l/h/kg and 2.37 l/kg, respectively).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),[l] / [h·kg],2.17,251387,DB01268,Sunitinib
,24778032,systemic clearance,"The corresponding pharmacokinetic parameters of systemic clearance and volume of distribution at steady-state of sunitinib were significantly larger in analbuminemic rats (2.17 l/h/kg and 3.94 l/kg, respectively) than those in SD rats (1.26 l/h/kg and 2.37 l/kg, respectively).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),[l] / [h·kg],1.26,251388,DB01268,Sunitinib
,24778032,volume of distribution at steady-state,"The corresponding pharmacokinetic parameters of systemic clearance and volume of distribution at steady-state of sunitinib were significantly larger in analbuminemic rats (2.17 l/h/kg and 3.94 l/kg, respectively) than those in SD rats (1.26 l/h/kg and 2.37 l/kg, respectively).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),[l] / [kg],3.94,251389,DB01268,Sunitinib
,24778032,volume of distribution at steady-state,"The corresponding pharmacokinetic parameters of systemic clearance and volume of distribution at steady-state of sunitinib were significantly larger in analbuminemic rats (2.17 l/h/kg and 3.94 l/kg, respectively) than those in SD rats (1.26 l/h/kg and 2.37 l/kg, respectively).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),[l] / [kg],2.37,251390,DB01268,Sunitinib
,24778032,unbound fraction,"In in vitro protein-binding experiments using an equilibrium dialysis method, the binding profiles of sunitinib in SD and analbuminemic rats were linear, and the unbound fraction in analbuminemic rats (0.110) was significantly larger than that of SD rats (0.062).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),,0.110,251391,DB01268,Sunitinib
,24778032,unbound fraction,"In in vitro protein-binding experiments using an equilibrium dialysis method, the binding profiles of sunitinib in SD and analbuminemic rats were linear, and the unbound fraction in analbuminemic rats (0.110) was significantly larger than that of SD rats (0.062).","Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24778032/),,0.062,251392,DB01268,Sunitinib
,20485286,MTD,"With growth-factor support, the MTD of sunitinib combined with either ifosfamide schedule was 12.5 mg in 32 patients enrolled.",Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20485286/),mg,12.5,255391,DB01268,Sunitinib
,20485286,MTD,"With growth-factor support, the MTD of sunitinib with both ifosfamide schedules was 12.5 mg.",Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20485286/),mg,12.5,255392,DB01268,Sunitinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,8,258264,DB01268,Sunitinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,17,258265,DB01268,Sunitinib
,22180047,Plasma terminal elimination half-lives,"Plasma terminal elimination half-lives of sunitinib were 8 h in rats, 17 h in monkeys, and 51 h in humans.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),h,51,258266,DB01268,Sunitinib
,22180047,bioavailability,"The bioavailability in female rats was close to 100%, suggesting complete absorption of sunitinib.","Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22180047/),%,100,258267,DB01268,Sunitinib
,22179104,maximum tolerated dose,A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day.,Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179104/),[mg] / [m],15,264425,DB01268,Sunitinib
,22179104,peak plasma sunitinib concentration,A median peak plasma sunitinib concentration of 21 (range 6-36) ng/ml was reached at a median of 4 (range 4-8) h after the first dose.,Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179104/),[ng] / [ml],21,264426,DB01268,Sunitinib
,22179104,AUC(0-48)),"The median exposure (AUC(0-48)) was 585 (range 196-1,059) h ng/l.",Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179104/),[h·ng] / [l],585,264427,DB01268,Sunitinib
,22179104,half-life,The median half-life was 23 (range 13-36) h.,Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179104/),h,23,264428,DB01268,Sunitinib
,22179104,trough concentration,The median trough concentration measured before day 14 dosing was 32 (range 12-58) ng/ml.,Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22179104/),[ng] / [ml],32,264429,DB01268,Sunitinib
,22259028,flow-rate,"Chromatographic separation was achieved on a Waters X-Terra® MS RP(18) column with a mobile phase consisting of acetonitrile and water (60:40, v/v) containing formic acid (0.1%, v/v) using an isocratic run, at a flow-rate of 0.2 mL/min.",Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22259028/),[ml] / [min],0.2,268022,DB01268,Sunitinib
